[go: up one dir, main page]

WO2008129529A3 - Cannabinoïde pour le traitement des lésions neuronales chez les patients diabétiques - Google Patents

Cannabinoïde pour le traitement des lésions neuronales chez les patients diabétiques Download PDF

Info

Publication number
WO2008129529A3
WO2008129529A3 PCT/IL2008/000477 IL2008000477W WO2008129529A3 WO 2008129529 A3 WO2008129529 A3 WO 2008129529A3 IL 2008000477 W IL2008000477 W IL 2008000477W WO 2008129529 A3 WO2008129529 A3 WO 2008129529A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuronal damage
cannabinoid
treatment
diabetic patients
tetrahydrocannabinol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2008/000477
Other languages
English (en)
Other versions
WO2008129529A2 (fr
Inventor
Elliot Berry
Raphael Mechoulam
Yosefa Avraham
Yossi Dagon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of WO2008129529A2 publication Critical patent/WO2008129529A2/fr
Publication of WO2008129529A3 publication Critical patent/WO2008129529A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'une quantité effective d'au moins un cannabinoïde sélectionné dans un groupe consistant de HU-210 et de tétrahydrocannabinol (THC) pour la fabrication d'une composition pharmaceutique pour l'atténuation de la lésion neuronale due à l'hyperglycémie, ou pour le traitement de la lésion neuronale chez un sujet diabétique, dans laquelle HU-210 est l'analogue (+)-1,1-diméthylheptyl du 7-hydroxy-delta-6- tétrahydrocannabinol de formule :
PCT/IL2008/000477 2007-04-19 2008-04-06 Cannabinoïde pour le traitement des lésions neuronales chez les patients diabétiques Ceased WO2008129529A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91272007P 2007-04-19 2007-04-19
US60/912,720 2007-04-19
IL190531 2008-03-31
IL190531A IL190531A0 (en) 2008-03-31 2008-03-31 Cannabinoid for the treatment of neuronal damage in diabetic patients

Publications (2)

Publication Number Publication Date
WO2008129529A2 WO2008129529A2 (fr) 2008-10-30
WO2008129529A3 true WO2008129529A3 (fr) 2008-12-24

Family

ID=39764920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/000477 Ceased WO2008129529A2 (fr) 2007-04-19 2008-04-06 Cannabinoïde pour le traitement des lésions neuronales chez les patients diabétiques

Country Status (2)

Country Link
IL (1) IL190531A0 (fr)
WO (1) WO2008129529A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006226A1 (fr) * 2006-07-14 2008-01-17 Wine, Harvey Formulations transdermiques de cannabinoïdes de synthèse et de silice nanocolloïdale

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006226A1 (fr) * 2006-07-14 2008-01-17 Wine, Harvey Formulations transdermiques de cannabinoïdes de synthèse et de silice nanocolloïdale

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CAMERON NORMAN ET AL: "The cannabinoid agonist, WIN555212-2, corrects nerve and vascular dysfunction in diabetic rats.", DIABETES, vol. 52, no. Supplement 1, 2003, & 63RD SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION; NEW ORLEANS, LA, USA; JUNE 13-17, 2003, pages A4 - A5, XP009106950, ISSN: 0012-1797 *
DAGON ET AL: "The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 27, no. 2, 26 July 2007 (2007-07-26), pages 174 - 181, XP022169195, ISSN: 0969-9961 *
DOGRUL A ET AL: "Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 368, no. 1, 16 September 2004 (2004-09-16), pages 82 - 86, XP004549487, ISSN: 0304-3940 *
LI XINGUANG ET AL: "Examination of the immunosuppressive effect of DELTA9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 1, no. 4, April 2001 (2001-04-01), pages 699 - 712, XP002499429, ISSN: 1567-5769 *
MARSICANO GIOVANNI ET AL: "Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1", JOURNAL OF NEUROCHEMISTRY, vol. 80, no. 3, February 2002 (2002-02-01), pages 448 - 456, XP002499428, ISSN: 0022-3042 *
SCOTT DAVID A ET AL: "Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat", PAIN, vol. 109, no. 1-2, May 2004 (2004-05-01), pages 124 - 131, XP002499430, ISSN: 0304-3959 *
ULUGOL A ET AL: "The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 371, no. 2-3, 23 November 2004 (2004-11-23), pages 167 - 170, XP004618552, ISSN: 0304-3940 *
WILLIAMS JOVAN ET AL: "Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 584, no. 1, April 2008 (2008-04-01), pages 78 - 86, XP022561529, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
WO2008129529A2 (fr) 2008-10-30
IL190531A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
NZ589228A (en) Combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) for the treatment of a brain tumour
UA100384C2 (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
WO2009001362A3 (fr) Compositions de plantes pour le traitement du diabète et/ou de maladies associées à celui-ci
WO2008108958A8 (fr) Dérivés de benzimidazole et leurs procédés d'utilisation
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
NZ597704A (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
MX2009009417A (es) Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
WO2008097640A3 (fr) Composés à base de triazole modulant l'activité de hsp90
BRPI0519803A2 (pt) métodos para purificar trans-(-)-delta9-tetraidrocanabinol e trans-(+)-delta9-tetraidrocanabinol
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2009098072A3 (fr) Composition destinée à traiter le stress oxydatif
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
WO2010028132A3 (fr) Nouveaux co-cristaux de choline et d'épalrestat
WO2007138466A3 (fr) Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
BRPI0716985A2 (pt) Composição nutricional, uso da mesma, e, suplemento nutricional para o tratamento de pacientes que sofrem de alergias a alimentos
WO2010011926A3 (fr) Nouveau co-cristal de bétaïne d'épalrestat
WO2008155390A3 (fr) Utilisation d'inhibiteurs de sirtuines et/ou de l'ampk dans la préparation d'un médicament destiné au traitement des maladies à polyalanine
WO2011052935A3 (fr) Composition destinée à réduire la glycémie, contenant un extrait de smilax china l., de momordica charantia et de cordyceps militaris comme principe actif
Rafieian-Kopaei et al. Green tea and type 2 diabetes mellitus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720069

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08720069

Country of ref document: EP

Kind code of ref document: A2